Arbutus Biopharma (ABUS) Reports In-Line Q1 EPS

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print